Sex determination in flies relies on the different ratio of X chromosomes to autosomes in XX females and XY males. Mammals have a maledetermining Y-linked gene, but may retain dosage-related elements.
The existence of two sexes is a general theme in animal biology. It might be expected that this commonality would be reflected in conservation of the genetic mechanisms that control whether an individual develops as a male or a female. Unfortunately, this expectation has been confounded by comparison of the chromosomal sex-determination mechanisms of Caenorhabditis elegans, Drosophila melanogaster and mammals. C. elegans and Drosophila both depend on dosage of the X chromosome for the primary sex-determining signal, but the way the signal is propagated in the sex-determination pathway differs between the two: worms use a genetic control pathway that is regulated at the level of transcription, whereas the fruitfly pathway is regulated posttranscriptionally, by modification of splicing patterns.
For many years, it was assumed that humans and other mammals also use dosage of the X chromosome for sex determination. This assumption was dispelled by cytogenetic analyses of individuals with unusual sex-chromosome constitutions. Normal females have two X chromosomes and normal males an X and a Y chromosome. But individuals with a single X chromosome and no Y chromosome are female, whereas those with multiple X chromosomes and a single Y develop as males. Mammals therefore have a dominant Y chromosome that is needed for male sex determination. In the past three decades, a major emphasis of research in mammalian sex determination has been the identification of the inducer of male differentiation that is on the Y chromosome. But a recent series of papers have raised the possibility that remnants of a dosage-dependent sex-determination mechanism are still present in mammals.
Sex determination in flies and worms
Female and male Drosophila have the same sex chromosome genotypes as female and male mammals -XX and XY, respectively. The primary signal for sex determination in flies is the ratio of the number of X chromosomes to the number of sets of autosomes -the X:A ratio [1, 2] . Hence, in females, the X:A ratio is 1, and in males it is 2½. The Y chromosome is needed for fertility of the male fly but is irrelevant for male sex determination. The protein encoded by the autosomal deadpan (dpn) gene, in conjunction with a maternally provided gene product, extra-*The Genetics Review Group: Vanessa King, Richard Korn, Cheni Kwok, Yashin Ramkissoon, Veronique Wunderle and Peter Goodfellow. The limiting factor in these interactions is the amount of Sis protein present, as both XX and XY organisms have equal amounts of Dpn and Emc. Males, which have only one X chromosome, have too little free Sis protein to bind all the available Dpn and Emc; Sis also binds to the product of another maternally provided gene, daughterless (da). Females have enough Sis protein to allow them to accumulate sufficient Da-Sis heterodimers to go on and initiate activation of the sex-determining gene, Sex lethal (Sxl) from its early promoter. Active 'early' Sxl protein, which is present only in females, initiates the production of active 'late' Sxl proteins from a different promoter within the sxl gene. The presence or absence of the late Sxl protein directs the course of a cascade of sex-specific splicing interactions, which result in the production of female or male morphogens, respectively. Thus, sxl is central to the initial sex-determining steps of sexually dimorphic development in the fly. But there is a potential problem that arises as a result of the very different genetic content of the fruitfly sex chromosomesthe Y chromosome being almost bereft of genes -and that is the problem of differential dosage of X-linked genes between males and females later in development. This has been solved by a two-fold increase in the expression of X-linked genes in males, so that they receive as much of each gene product as females do. This dosage compensation, like initial sex determination, is controlled by Sxl.
The male genotype in C. elegans is XO, with XX animals being hermaphrodite. As in Drosophila, the X:A ratio regulates both sex determination and dosage compensation. In XO animals, in response to the X:A ratio of ½, the xol-1 gene product is produced, and this protein negatively regulates sex-linked genes that are essential for female differentiation and dosage compensation. Unlike dosage-compensation in Drosophila, in which expression from the male X chromosome is up-regulated, in C. elegans there is a reduction in the level of expression from the two X chromosomes in XX animals. ridge during fetal development. The testis-inducing, and therefore male-determining, factor was named TDF (testis-determining factor). In 1990, the SRY (sex-determining region of Y) gene was cloned from the short arm of the Y chromosome [4] , and it has now been proven that SRY is the TDF. Mutations in the SRY open reading frame are found in 'sex-reversed' XY female patients, who are female despite having an apparently male chromosome complement [5, 6] , and XX mice given a transgenic copy of the murine Sry gene develop as males [7] . The strict temporal and spatial regulation of SRY expression suggests that there are genes upstream that regulate its expression. Furthermore, the DNA-binding properties of the SRY protein suggest that it regulates elements further down the sex-determination pathway. In terms of the dosage-compensation problem, the mammalian chromosome shares very few genes with the X chromosome, and mammals have evolved a dosage-compensation system whereby one X chromosome is largely transcriptionally inactivated in each female cell [8] .
A link between dosage and sex determination in mammals
In 1980, Bernstein and colleagues [9] described two sexreversed sisters who had inherited an apparently normal Y chromosome and an X chromosome with an interstitial duplication of part of the short arm of the X chromosome. Several similar patients were subsequently described. As the duplications were overlapping, but did not have a common breakpoint, these results suggested the presence of a gene on the X chromosome -named DSS, for dosage-sensitive sex-reversal -that when present in two active copies can override the effect of the Y chromosome. In XXY individuals, this gene would be subject to X-inactivation, allowing male development.
The screening of sex-reversed XY females who do not have cytological abnormalities, using markers from the short arm of the X chromosome, identified submicroscopic duplications, and these allowed refinement of the position of DSS to a 160-kilobase stretch within the Xp21 region [10] . Fortuitously, this region of the genome had previously been cloned for the study of a syndrome that involves contiguous genes and is manifest as adrenal hypoplasia congenita (AHC), glycerol kinase deficiency and Duchenne muscular dystrophy. As part of the search for genes, the region was analyzed for so-called CpG islands, motifs that are characteristic of transcribed regions of the genome. A single CpG-rich region was found within the 160-kilobase DSS region, and adjacent sequences, which showed evolutionary conservation, were used to isolate cDNA clones from adult human testis and fetal adrenal libraries. The cDNA clones revealed a previously unknown gene that encodes a novel member of the nuclear hormone-receptor superfamily. Point mutations in the gene were found in patients with AHC, and the gene was named DAX-1 (the first gene in the DSS-AHC-critical region of the X chromosome) [11] .
AHC is a developmental disease in which the adrenals fail to form properly. The close embryological relationship between adrenals and gonads, and their shared steroidogenic properties, support the hypothesis that DAX-1 might be both the DSS gene and responsible for AHC. However, mutations in DAX-I1 that cause adrenal hypoplasia do not affect testis development, and Zanaria and colleagues [11] have failed to find mutations of DAX-1 in a preliminary screen of 30 XY females. There is a good chance that DAX-1 is not the only gene in the DSS region. A region of 160 kilobases would be expected to contain (on average) three to five genes, and 60 % of all genes -but only 40% of tissue-specific genes -contain CpG islands [12] , so there is a possibility that other genes would have been missed by the CpG-screening strategy.
Despite the uncertainty about whether DAX1 is indeed the DSS gene, it is still possible to deduce some of the remarkable properties of DSS. Large deletions that completely remove the DSS-AHC-critical region are compatible with testis development, so DSS must not be needed in males, but two active copies result in ovarian development in XY individuals (Fig. 1) . One obvious possibility is that DSS is required for ovarian development and must be repressed in order to allow testes to form. This model predicts that XX patients without DSS would fail to form ovaries.
If SRY has overridden an ancestral dosage mechanism of sex determination to become the sole TDF we would expect that the original key sex-determining gene was X-linked. A plausible scenario is that DSS interacted in a dose-dependent fashion with an SRY-related gene, and that SRY captured the sex-determination pathway at this point. Eventually, X inactivation obscured any lingering sex-determining properties of DSS. This view might explain the rapid evolution of SRY, and leads to the prediction that dosage-dependent SRY-related genes may be still present in the mammalian sex-determination pathway. The discovery of a dosage-dependent element in the mammalian pathway suggests similarities with the fly and worm, but the remaining differences between the three best-studied systems of sex determination are still many and varied.
